FindTrial
Sign In

Pilot study on tolerability of specific immunotherapywith injective allergoid adsorbed on calcium phosphate in patients with respiratory allergy to house dust mite. - ND

Pilot study on tolerability of specific immunotherapywith injective allergoid adsorbed on calcium phosphate in patients with respiratory allergy to house dust mite. - ND

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-003058-26-IT
Enrollment
Unknown
Registered
2007-10-05
Start date
2007-07-17
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergic rhinoconjunctivitis with or without asthma MedDRA version: 9.1 Level: LLT Classification code 10039085 Term: Rhinitis allergic

Interventions

Product Name: Dermatophagoides injective allergoid Pharmaceutical Form: Suspension for injection Current Sponsor code: ModAll-Der Concentration unit: IU international unit(s) Concentration type: equal

Sponsors

LOFARMA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: -rhinoconjunctivitis with or without asthma due to allergy to house-dust mite - age: 18-50 years Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: - FEV < 75% - atopic dermatitis or food allergy - patients with previous serious anaphylactic reactions - pregnancy and lactatio - severe systemic diseases

Design outcomes

Primary

MeasureTime frame
Main Objective: tolerability evaluation;Secondary Objective: safety evaluation;Primary end point(s): tolerability evaluation—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026